$1.86
-0.26%Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Steady FCF growth indicates consistent cash generation improvement. On a positive trajectory.
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
SEER โข NASDAQ
| Seer, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||
-73.6M | -86.6M | -86.3M | -93M | -71.2M | -32.8M | -16M | -6.3M | |
7.2M | 6.2M | 5.6M | 3.9M | 2.6M | 1.6M | 701K | 31K | |
0.0 | 0.0 | 0.0 | 0.0 | 1.2M | 0.0 | -259K | 0.0 | |
15.4M | 28.2M | 34.4M | 33.7M | 25.9M | 7.3M | 1.6M | 672K | |
7.1M | 6.3M | -10.1M | 1.7M | 1M | 271K | 5K | 549K | |
(0.0) | (154K) | (0.0) | (232K) | (645K) | (0.0) | (0.0) | (0.0) | |
-579K | -144K | -2.7M | -7.1M | -5.9M | 2.7M | 961K | 953K | |
-44.4M | -46.1M | -59.1M | -60.8M | -46.3M | -20.8M | -13.1M | -4.7M | |
INVESTING ACTIVITIES | ||||||||
-1.8M | -3.6M | -7.3M | -10.3M | -6.9M | -4.5M | -4.1M | -168K | |
(0.0) | (0.0) | (0.0) | (0.0) | (164M) | -50K | (68.3M) | (0.0) | |
-173.2M | -272.9M | -403.1M | -366.3M | -280M | -87.7M | -92M | (0.0) | |
237.8M | 342M | 448.3M | 253.6M | 116M | 57.8M | 23.8M | 0.0 | |
-1.3M | 343K | 0.0 | 170K | -164M | 0.0 | -68.3M | 0.0 | |
(61.5M) | (65.9M) | (37.9M) | -122.7M | -170.9M | -34.6M | -72.4M | -168K | |
FINANCING ACTIVITIES | ||||||||
-9.7M | -11.8M | -13K | -20K | 102.9M | 315.3M | -6K | 51K | |
-10.2M | -11.8M | -13K | -20K | -35K | -13K | -6K | (0.0) | |
-827K | 321K | 465K | 3.9M | 13.7M | 1.3M | 406K | 29.9M | |
-10.6M | -11.5M | 452K | 3.9M | 116.6M | 371.5M | 72.3M | 29.9M | |
CASH FLOW SUMMARY | ||||||||
6.5M | 8.3M | -20.7M | -179.6M | -100.6M | 316.1M | -13.1M | 25.1M | |
41.3M | 33M | 53.7M | 233.3M | 333.9M | 17.8M | 31M | 5.8M | |
47.8M | 41.3M | 33M | 53.7M | 233.3M | 333.9M | 17.8M | 31M | |
-46.2M | -49.7M | -66.4M | -71M | -53.3M | -25.4M | -17.2M | -4.8M |
SEER - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 22, 2026 | May 21, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 13, 2026 | May 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 04, 2026 | May 04, 2026 | 2026 | |
10-K/A 10-K/A 2025 FY (Amended) FY | April 30, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | April 27, 2026 | April 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 13, 2026 | April 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 30, 2026 | March 23, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 16, 2026 | March 13, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 02, 2026 | December 31, 2025 | 2025 |
Continue your SEER research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.